|
Apr 29
|
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
|
|
Apr 28
|
Private Equity Firms Target Defense Assets Once Seen as Toxic
|
|
Apr 25
|
Swiss Agree to Tariff Negotiations With Trump Administration
|
|
Apr 24
|
Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed
|
|
Apr 24
|
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
|
|
Apr 24
|
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
|
|
Apr 23
|
Why vaccine makers aren't worried about Trump administration cuts
|
|
Apr 19
|
Regeneron, Sanofi announce FDA approval of Dupixent for CSU
|
|
Apr 18
|
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
|
|
Apr 18
|
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
|
|
Apr 18
|
Stocks to watch this week: Tesla, Alphabet, Intel, Boeing and Unilever
|
|
Apr 15
|
Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement
|
|
Apr 9
|
Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’
|
|
Apr 8
|
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
|
|
Mar 14
|
Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
|
|
Feb 22
|
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
|
|
Feb 22
|
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
|
|
Feb 19
|
Press Release: Sanofi and CD&R sign Opella share purchase agreement
|
|
Feb 18
|
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
|
|
Feb 7
|
Press Release: Execution of a share buyback agreement for up to €2 billion
|